Tower Research Capital (TRC)’s ENDRA Life Sciences NDRA Stock Holding History

Tower Research Capital (TRC)’s Portfolio NDRA Stock Details NDRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-225	Closed	-$1.21K	–	5440
2025 Q3	$1.21K	Buy	+225	New	+$1.18K	﹤0.01%	4844
2025 Q2	–	Sell	-1,130	Closed	-$4.63K	–	5467
2025 Q1	$4.63K	Buy	+1,130	New	+$5.47K	﹤0.01%	4227
2024 Q4	–	Sell	-466	Closed	-$3.28K	–	5898
2024 Q3	$3.28K	Buy	466 +447	+2,353%	+$34.6K	﹤0.01%	4873
2024 Q2	$3.3K	Buy	19 +14	+280%	+$6.03K	﹤0.01%	4906
2024 Q1	$5.02K	Buy	5 +3	+150%	+$5.88K	﹤0.01%	4595
2023 Q4	$6.32K	Sell	2 -2	-50%	-$4.21K	﹤0.01%	4757
2023 Q3	$8.24K	Buy	4 +3	+300%	+$6.41K	﹤0.01%	4371
2023 Q2	$3.49K	Buy	+1	New	+$2.82K	﹤0.01%	5066
2023 Q1	–	Hold	0	–	–	–	6123
2022 Q4	–	Sell	-1	Closed	-$8.38K	–	6197
2022 Q3	$8K	Hold	1	–	–	﹤0.01%	4796
2022 Q2	$9K	Hold	1	–	–	﹤0.01%	4574
2022 Q1	$8K	Buy	+1	New	+$17.9K	﹤0.01%	4598
2021 Q4	–	Hold	0	–	–	–	6415
2021 Q3	–	Hold	0	–	–	–	6025

Other funds holding NDRA

ACM

Altium Capital Management New York $42M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Tower Research Capital (TRC)'s NDRA Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of ENDRA Life Sciences (NDRA) in Q4 2025, closing a stake of 225 shares — an estimated $1.21K sold.

Tower Research Capital (TRC) first reported a position in NDRA in Q1 2022 and held it in 11 quarters. The position peaked at $9K in Q2 2022. 7 funds tracked by Wall St. Rank hold NDRA as of Q4 2025.

Tower Research Capital (TRC) reported no remaining ENDRA Life Sciences position as of Q4 2025 after selling out during the quarter.
Tower Research Capital (TRC) sold 225 ENDRA Life Sciences shares in Q4 2025, an estimated $1.21K.
Tower Research Capital (TRC) first reported a position in ENDRA Life Sciences in Q1 2022 and held it in 11 quarters.
Tower Research Capital (TRC)'s ENDRA Life Sciences position peaked at $9K in Q2 2022.
7 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.